medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 4

<< Back Next >>

Med Int Mex 2007; 23 (4)

Insulin analogues

Frenk BP, Escalante-Pulido M

Language: Spanish
References: 78
Page: 310-320
PDF size: 281.49 Kb.


ABSTRACT

Most of studies has demonstrated that patients with good glycemic control reduce retinopathies and its progression, and nephropathies and neuropathies due to diabetes. The aim of insulin analogues is to control hypoglycemic and hyperglycemic levels. These analogues replace certain aminoacids at a and b chains of insulin molecule, which gives it specific pharmacodynamic properties as: replication of most physiological profile of human insulin, and improving of glycemic control and patients quality of life. This revision deals with current alternatives related to insulin analogues on diabetes mellitus treatment.


REFERENCES

  1. Howard ML. The new designer insulins. Clin Diabetes 2000;18:1-13.

  2. Lee LM, Zinman B. From insulin to insulin analogs: progress in the treatment of type 1 diabetes. Diabetes 1998;6:73-88.

  3. Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophthalmol 1998;106:1242-6.

  4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

  5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin, compared with conventional treatment and risk of complications patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

  6. Gomez-Perez FJ, Rull AJ. Insulin therapy: current alternatives. Arch Med Res 2005;36;258-72.

  7. Rull JA, Garcia-Viveros, Gomez Perez FJ, Valles V, Lozano- Castañeda O. Insulin response to normal diet. Recent advances in endocrinology. Excerpta Medica, International Congress Series 1970;238:442-49.

  8. Zinman B. The Physiologic replacement of insulin. An elusive goal. N Engl J Med 1989;321:363-70.

  9. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 1997;40(Suppl 2);S54- S61.

  10. Bolli GB, DiMarchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.

  11. Kotsanos JG, Vignati L, Huster W, Andrejasich C, et al. Health related quality of life results form multinational clinical trials of insulin lispro. Diabetes Care 1997;20:948-58.

  12. Glazer NB, Zalani S, Anderson JH, Bastyr EJ. Safety of insulin lispro: pooled data from clinical trials. Am J Health Syst Pharm 1999;56:542-7.

  13. Heller SR, Amiel SA, Mansell P. Effect of the fast acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro study Group. Diabetes Care 1999;22:1607-11.

  14. Holleman F, Schmitt H, Rottiers R, Rees A, et al. Reduced frequency of severe hypoglycemia and coma in well controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997;20:1827-32.

  15. Bhattacharya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy (abstract). QMJ 2001;94(12):255- 60.

  16. Jovanovic L, Ilic S, Pettit DJ. The metabolic and immunological effects of insulin lispro in gestational diabetes. Diabetes Care 1999;22;1422-27.

  17. Garg S, Pennington M, Anderson A. Maternal and fetal outcomes between human regular and Humalog insulin treated pregnancies in type 1. Diabetologia 1999;48(Suppl 1):A437. (Abstract).

  18. Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999;22:874-5.

  19. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002;113:308-16.

  20. Kang S, Creagh FM, Peters JR, Orange J, et al. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9; GluB27; AspB10; AspB28) on meal related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care 1991;14:571-7.

  21. Home PD, Lindhom A, Riis A. Insulin aspart vs. human insulin in the management of long term blood glucose control in type 1 diabetes mellitus; a randomized controlled trial. Diabet Med 2000;17:262-70.

  22. Setter SM, Corbett CF, Campbell RK, White JR. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 2000;34:1423-31.

  23. Kang S, Brange J, Burch A, Volund A, Owens D. Subcutaneous insulin absorption explained by insulin’s physicochemical properties; evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 1991;14;942-8.

  24. Heinemann L, Kapitza C, Starke AA, Heise T. Time action profile of the insulin analogue B28Asp. Diabet Med 1996;13:683-4.

  25. Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 2001;24;1120-1.

  26. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998;21:1904-9.

  27. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind crossover trial in type 1 diabetes. Diabetes Care 1999;22:801-5.

  28. Becker R, Frick A, Wessels D, Scholtz H. Pharmacodynamics and pharmacokinetics of a new, rapidly acting insulin analog, insulin glulisine. Diabetes 2003;52(Suppl 1):A110.

  29. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2362-8.

  30. Rakatzi I, Seipke G, Eckel J. (LysB3, GluB29) insulin: a novel insulin analog with enhanced B-cell protective action. Biochem Biophys Res Commun 2003;310(3):852-9.

  31. Rakatzi S, Ramrath D, Ledwig O, Dransfed T, et al. A novel insulin analog with unique properties: LysB28, GluB29 insulin induces prominent activation of IRS-2 but marginal phosphorylation of IRS-1. Diabetes 2003;52(9):2227-38.

  32. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7:188-99.

  33. Owens DR, Coates PA, Luzio SD, Timbergen JP, Kurzhals R. Pharmacokinetics of 125 I-labeled insulin glargine (HOE 901) in healthy man: comparison with NPH insulin and the influence of different subcutaneous injections sites. Diabetes Care 2000;23:813-9.

  34. White JR, Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med 1997;101:58-60,63-65,70.

  35. Heinemman L, Linkeschova R, Rave K, Hompesch B, et al. Time-action profile of the long acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.

  36. Raskin P, Klaff L, Bergenstal R, Hallé JP, et al. A 16 week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:639-43.

  37. Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post- dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1666-71.

  38. Ratner RE, Hirsch IB, Neifing JL, Garg SK, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. study Group of insulin Glargine in type 1 diabetes. Diabetes Care 2000;23:639-43.

  39. Girish C, Manikandan S, Jayanthi M. Newer insulin analogues and inhaled insulin. Indian J Med Sci 2006;60:3:117-23.

  40. Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004;26:445-61.

  41. Heise T, Nosek L, Ronn BB, Endahl L, et al. Lower-within subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.

  42. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, et al. Albumin binding of insulins acylated with fatty acids: characterizations of the ligand protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312:725-31.

  43. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care 2004;27:1081-7.

  44. Kurtzhals P, Hevelund S, Jonassen I, Kiehr B, et al. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996;85:304-8.

  45. Brunner GA, Sendhofer G, Wutte A, Ellmere M, et al. Pharmacokinetics and pharmacodymanic properties of long acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrionol Diabetes 2000;108:100-5.

  46. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen MA. Comparison of the basal insulin analogue, insulin detemir (NN304), with NPH insulin in the management of type 1 diabetic patients. Diabetes 2000;49(Suppl 1):446.

  47. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen MA. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-301.

  48. Danne T, Lupke K, Walte K, Von Scueetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-92.

  49. Vague P, Selam JL, Skeie S, DeLeeuw I, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care 2004;27:1081-87

  50. Heinemann L, Sinha K, Weyer C, Loftager M, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analog NN304. Diabet Med 1999;16:332-38.

  51. Vague P, Selam JL, Skeie S, De Leeuw I, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-96.

  52. Haak T, Tiengo A, Waldhausl W, Draeger E. Treatment with insulin detemir is associated with predictable fasting blood glucose levels and favorable weight development in subjects with type 2 diabetes. Diabetes Care 2003;52(Suppl 1):A120.

  53. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-89.

  54. Levemir [prescribing Information]. Novo Nordisk Inc. Dirección URL: [Consulta: 22 abril 2006].

  55. Schmitz O, Gray R, Kristensen A. Dose relationship between insulin detemir and NPH: a multicenter, open, two-period trial in type 2 diabetic patients. Program and abstracts of the 37th Annual Meeting of the European Association for the Study of Diabetes (EASD); September 9-13, 2001; Glasgow, United Kingdom.

  56. Raslová K, Bogoev M, Raz I, Leth G, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.

  57. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005;48:420-6.

  58. Garber A, Wahlen J, Wahl T, Bressler P, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice- daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006;8:56-66.

  59. Janka HU, Plewe G, Riddle MC. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9.

  60. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999;22(8):1258-61.

  61. Heise T, Weyer C, Serwas A, Heinrichs S, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998;21(5):800-3.

  62. Rave K, Heinemann L, Puhl L, Gudat U, et al. Premixed formulations of insulin lispro: Activity profiles in type 1 diabetic patients. Diabetes Care 1999;22(3):865-6.

  63. Malone JK, Woodworth JR, Arora V, Yang H, et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000;22(2):222-30.

  64. Reviriego J, Herz M, Roach P. Improved glycaemic control without increased risk of hypoglycaemia with 25% insulin/lispro75% NPL mixture twice daily compared with NPH twice daily in patients with type 2 diabetes. J Appl Therap Res 2004;4:3-9.

  65. Malone JK, Wolthers T, Sun B. Improvement in HbA1c in patients with type 2 diabetes with Humalog® Mix25 versus basal human insulin: a double-blind study. J Applied Ther Res 2004;4:19-25.

  66. Herz M, Sun B, Milicevic Z, Ericsson P, et al. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther 2002;24:73-86.

  67. Roach P, Koledova E, Metcalfe S, Hultman C, Milicevic Z. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther 2001;23(10):1732-44.

  68. Milicevic Z, Herz M, Rashwan AR. Comparison of conventional insulin regimen with lispro mixture 25 vs. combined oral treatment in patients failing sulfonylurea monotherapy [abstract]. Presented at American Diabetes Association Meeting in San Francisco, CA, 2002.

  69. Milicevic Z, Herz M, Ivanyi T. Sulfonylurea and bedtime NPH insulin vs. Humalog Mix50 (Mix25) before dinner in patients failing combined oral treatment [abstract]. Diabetes 2002;51(Suppl 2):A475.

  70. Holcombe JH, Zagar A, Pinaire JA. Superiority of insulin lispro 75/25 (LM) compared with NPH when used in combination with metformin (MET). Diabetes 2005;51:A101.

  71. Janssen M, Casteleijn S, Devillé W, Popp-Snijders C, et al. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediateacting lispro preparation. Diabetes Care 1997;20(12):1870-3.

  72. Roach P, Arora V, Campaigne BN, Mattoo V, Ranwala S. Humalog Mix25 before carbohydrate-rich meals in patients with type 2 diabetes. Diabetes Obes Metab 2005;5:311-6.

  73. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485-91.

  74. Glueck CJ, Goldenberg N, Streicher P, Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002;3:1557-68.

  75. Glueck CJ, Goldenberg N, Streicher P, Wang P. Metformin and gestational diabetes. Curr Diab Rep 2003;3:303-12.

  76. Jovanovic L, Ilic S, Pettitt DJ. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999;22:1422-7.

  77. Pettit DJ, Ospina P, Kolaczynski JW. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 2003;26:183-6.

  78. Yogev Y, Langer O. The use of anti-hyperglycaemic and hypoglycaemic agents in pregnancy. Fetal Matern Med Rev 2004;15:133-43.




2020     |     www.medigraphic.com